

Special Issue

The Current Status of Treatment for Oligometastatic Lung Cancer

Message from the Guest Editor

The emergence of effective systemic therapies, such as immune checkpoint inhibitors and molecular-targeted therapies, along with the advent of precision medicine, has improved survival outcomes in advanced non-small-cell lung cancer. However, only a fraction of cases can avoid recurrence or progression. In this context, there has been increased awareness of the disease state, known as "oligometastases", and a multidisciplinary treatment strategy combining systemic and local ablative therapies has been explored for certain patients, potentially aiming to develop a cure. The primary local treatment for oligometastatic lung cancer is radiation therapy, with high-precision radiation therapy being central to local ablative therapy in several ongoing randomized phase III trials. Studies exclusively focused on surgical treatment for oligometastatic lung cancer have been limited, although there are situations where surgical treatment is prioritized for local lesions. It is essential to clarify the criteria for local ablative therapy and to classify oligometastatic states systematically to develop an effective oligometastatic lung cancer treatment strategy in the future.

Guest Editor

Dr. Yoshihisa Shimada
Department of Thoracic Surgery, Tokyo Medical University Hospital,
Tokyo, Japan

Deadline for manuscript submissions

closed (15 May 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/205760

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)